SIGA Technologies, Inc. (NASDAQ:SIGA) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET

Company Participants

Phil Gomez - Chief Executive Officer

Dan Luckshire - Chief Financial Officer

Conference Call Participants

Soo Romanoff - Edison Group

Operator

Ladies and gentlemen, greetings and welcome to the SIGA Technologies Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participants' lines are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or changed circumstances after this call.

For a discussion of factors that could cause results to differ, please see the company's filings with the Securities and Exchange Commission including without limitation the company's annual report on Form 10-K for the year ended December 31st, 2022 and its subsequent reports on Form 10-Q and Form 8-K.

It is now my pleasure to introduce you to Phil Gomez CEO. Please go ahead.

Phil Gomez

Thank you for taking the time to join today's call. Today I'm joined by Dan Luckshire, our CFO. We are pleased to have this opportunity to provide a business and financial update to our shareholders. We'll then be happy to take questions.

I'd like to start the call by recapping annual performance for 2022. On our prior year end investor call in March of 2022, we highlighted that 2022 would be a transition year with no significant expirations of oral TPOXX in the US Strategic National Stockpile or SNS.

I'm pleased to report we ended this past year with approximately $111 million in revenue for the year, thanks to a diversification of our revenue base. This diversification has been years in the making. And as a result we were prepared to respond to the global mpox or monkeypox outbreak. Our preparation included approval for treatment of mpox by the EMA in January of 2022 and our proactive build of inventory to be able to deliver TPOXX immediately to customers.

Overall, 2022 revenues included $71 million of sales took more than 10 international customers, the first sale of intravenous formulation of TPOXX to the US Government, and the first sales totaling approximately $7 million of oral TPOXX to the US Department of Defense.